Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABAT | P80404 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.44 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.43 |
| ▸ | ITGAV | P06756 | 1/20 | 0.43 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11625721 | 0.98 | ABAT (0.46) | ABATGAAMAPTKDM4EMEN1 | |
| SCHEMBL11585727 | 0.82 | CYP1A2 (0.47) | GAAMAPTKDM4EMEN1HPGD | |
| SCHEMBL6243640 | 0.82 | CA2 (0.47) | GAAMAPTKDM4EMEN1HPGD | |
| Hydrochloric Acid SCHEMBL11624632 | 0.82 | GAA (0.42) | GAAMAPTKDM4EMEN1HPGD | |
| Hippuric Acid SCHEMBL7486 | 0.78 | GAA (0.68) | GAAMAPTKDM4EALOX15SMN1; SMN2 | |
| SCHEMBL22030672 | 0.78 | GAA (0.68) | GAAMAPTKDM4EALOX15SMN1; SMN2 | |
| Hippuric Acid SCHEMBL428479 | 0.78 | GAA (0.68) | GAAMAPTKDM4EALOX15SMN1; SMN2 | |
| Hippuric Acid SCHEMBL3028 | 0.78 | MAPT (0.61) | GAAMAPTKDM4EHPGDSMN1; SMN2 | |
| Benzamide SCHEMBL27820629 | 0.77 | MAPT (0.57) | ABATGAAMAPTKDM4EMEN1 | |
| SCHEMBL7469076 | 0.77 | PTPRC (0.49) | MAPTKDM4ETDP1PTPRCALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1267369-B1 | Pyridine compound, its use as charge transfer material, and photoelectrochemical cell | FUJIFILM CORP (JP) | 2009-11-11 | — | — | EP | disclosed |
| US-20060270850-A1 | Processes for preparation of pyrimidine derivatives and intermediates | AJINOMOTO CO., INC. (JP) | 2006-11-30 | — | — | US | disclosed |
| EP-1695967-A1 | PROCESSES FOR PRODUCTION OF PYRIMIDINE DERIVATIVES AND INTERMEDIATES | Ajinomoto Co., Inc. (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-20050176966-A1 | Process for the preparation of pyrimidine derivative, intermediate therefor and process for the preparation thereof | AJINOMOTO CO., INC. (JP) | 2005-08-11 | — | — | US | disclosed |
| US-20050165234-A1 | Process for preparing pyrimidine compound | AJINOMOTO CO. INC (JP) | 2005-07-28 | — | — | US | disclosed |
| EP-1553090-A1 | PROCESS FOR PRODUCING PYRIMIDINE COMPOUND | Ajinomoto Co., Inc. (JP) | 2005-07-13 | — | — | EP | disclosed |
| EP-1529778-A1 | Production method of pyrimidine derivative, intermediate therefor | Ajinomoto Co., Inc. (JP) | 2005-05-11 | — | — | EP | disclosed |
| EP-0782991-B1 | Process for the preparation of 2-substituted 5-chloroimidazole-4-carbaldehydes | LONZA AG (CH) | 2002-04-17 | — | — | EP | disclosed |
| US-5696272-A | Process for the production of 2-substituted 5-chloroimidazole-4-carbaldehydes | LONZA LTD. (CH) | 1997-12-09 | — | — | US | disclosed |
| EP-0782991-A1 | Process for the preparation of 2-substituted 5-chloroimidazole-4-carbaldehydes | LONZA AG (CH) | 1997-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165234-A1 | Process for preparing pyrimidine compound | SERPINB1, CMA1, CTRC | ABAT 2104/4885GAA 54/4885MAPT 4138/4885 |
| US-20050176966-A1 | Process for the preparation of pyrimidine derivative, intermediate therefor and process for the preparation thereof | DPYD, WEE1, DCXR | ABAT 581/4885GAA 575/4885MAPT 4279/4885 |
| US-20060270850-A1 | Processes for preparation of pyrimidine derivatives and intermediates | PDXK, RNASEL, DPYD | ABAT 1498/4885GAA 385/4885MAPT 4778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.